NDA 214759 · Medexus
Grafapex
Treosulfan · Intravenous
NovelOrphanCDER novel approval, Jan 21, 2025: For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
Last checked: Nov 20, 2026Latest source record: Feb 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jan 21, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
51
10 Phase 3, 12 recruiting
FAERS reports
2,760
2,704 serious, 612 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MYELOSUPPRESSION GRAFAPEX causes severe and prolonged myelosuppression at the recommended dosage. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters [see Warnings and Precautions ( 5.1 )] . WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. GRAFAPEX causes severe and prolonged myelosuppression. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters. ( 5.1 )
What it is approved for
From the label in effect Jan 31, 2025.
GRAFAPEX is an alkylating drug indicated for: Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML). ( 1.1 ). Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS). ( 1.2 ). 1.1 Acute Myeloid Leukemia GRAFAPEX is indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML). 1.2 Myelodysplastic Syndrome GRAFAPEX is indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS).
Therapeutic areas: Hematology and blood cancers · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- GRAFAPEX · TREOSULFAN 1GM/VIAL · POWDER, INTRAVENOUS · Prescription
- GRAFAPEX · TREOSULFAN 5GM/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Treosulfan" as an intervention, any sponsor and status, largest first.
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01949129 · 1,800 participants (planned) · Start Apr 2013 · Primary completion Jun 1, 2030
Drug: VP16; Thiotepa and 6 more · For: Acute Lymphoblastic Leukaemia
Sites: Buenos Aires, Argentina; La Plata, Argentina; Melbourne, Australia · 119 sites in all
- Study in Localized and Disseminated Ewing SarcomaPivotal-lookingCompleted
University Hospital MuensterAcademic, hospital or other
NCT00987636 · 907 participants · Start Oct 1, 2009 · Primary completion Mar 31, 2019
Drug: Zoledronic acid; Busulfan and 1 more · For: Ewing's Sarcoma
Sites: Essen, Germany; Münster, Germany
- Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)Pivotal-lookingCompleted
medac GmbHIndustry
NCT00822393 · 570 participants · Start Nov 24, 2008 · Primary completion Jan 25, 2018
Drug: Busulfan; Treosulfan · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Sites: Helsinki, Finland; Lyon, France; Paris, France · 33 sites in all
- ALL-SCT BFM International- HSCT in Children and Adolescents With ALLPivotal-lookingStatus unknown
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01423500 · 405 participants (planned) · Start Jan 2007 · Primary completion Sep 2011
Drug: VP16; VP16, ATG and 2 more · For: Lymphoblastic Leukemia, Acute, Childhood;
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 24 sites in all
- Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingStatus unknown
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01423747 · 400 participants (planned) · Start Jul 2003 · Primary completion Sep 2011
Drug: VP16; VP16, ATG and 2 more · For: Lymphoblastic Leukemia, Acute, Childhood;
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 24 sites in all
- Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTICPivotal-lookingStatus unknown
University of WuerzburgAcademic, hospital or other
NCT00779714 · 360 participants (planned) · Start Oct 2008 · Primary completion Oct 2012
Drug: DTIC (dacarbazine); paclitaxel + cisplatin and 1 more · For: Melanoma
Sites: Aachen, Germany; Berlin, Germany; Bochum, Germany · 23 sites in all
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06083129 · 324 participants (planned) · Start Nov 28, 2023 · Primary completion Nov 28, 2028
Drug: Grafalon; Thymoglobulin · For: GVHD
Sites: Amiens, France; Angers, France; Besançon, France · 28 sites in all
- Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic TransplantationPivotal-lookingRecruiting
Technische Universität DresdenAcademic, hospital or other
NCT07025824 · 220 participants (planned) · Start Jan 21, 2026 · Primary completion Sep 2029
Drug: Treosulfan (Treo); Melphalan (Mel) and 1 more · For: AML - Acute Myeloid Leukemia; MDS (Myelodysplastic Syndrome)
Sites: Aachen, Germany; Augsburg, Germany; Berlin, Germany · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use687
- cytomegalovirus infection reactivation293
- cytomegalovirus infection262
- drug ineffective251
- mucosal inflammation243
- adenovirus infection240
- product use in unapproved indication228
- acute graft versus host disease in skin213
- graft versus host disease in skin168
- acute graft versus host disease139
- graft versus host disease in gastrointestinal tract134
- pyrexia132
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 30 |
| 2009 | 11 |
| 2010 | 14 |
| 2011 | 121 |
| 2012 | 21 |
| 2013 | 16 |
| 2014 | 35 |
| 2015 | 25 |
| 2016 | 65 |
| 2017 | 106 |
| 2018 | 229 |
| 2019 | 214 |
| 2020 | 275 |
| 2021 | 232 |
| 2022 | 204 |
| 2023 | 177 |
| 2024 | 291 |
| 2025 | 340 |
| 2026 | 338 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW, Trenschel R, Stelljes M, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Peters C, Dalle JH, Locatelli F, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Beelen DW, Stelljes M, Reményi P, et al. · Am J Hematol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study.
Bader P, Pötschger U, Dalle JH, et al. · Blood Adv 2024 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Leukemia following chemotherapy for ovarian cancer.
Kaldor JM, Day NE, Pettersson F, et al. · N Engl J Med 1990 · Clinical Trial, Multicenter Study
- Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia.
Klimentova M, Shelikhova L, Ilushina M, et al. · Transplant Cell Ther 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Medexus
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.